These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38608459)

  • 1. The impact of changing the reference countries on the list prices for patented medicines in Canada: A policy analysis.
    Zhang W; Guh DP; Grootendorst P; Hollis A; Anis AH
    Health Policy; 2024 Jun; 144():105064. PubMed ID: 38608459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of proposed price regulations on new patented medicine launches in Canada: a retrospective cohort study.
    Zhang W; Sun H; Guh DP; Grootendorst P; Hollis A; Anis AH
    CMAJ; 2024 May; 196(20):E691-E701. PubMed ID: 38802136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries.
    Leopold C; Mantel-Teeuwisse AK; Vogler S; de Joncheere K; Laing RO; Leufkens HG
    Health Policy; 2013 Oct; 112(3):209-16. PubMed ID: 24060335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of external price referencing on medicine prices - a price comparison among 14 European countries.
    Leopold C; Mantel-Teeuwisse AK; Seyfang L; Vogler S; de Joncheere K; Laing RO; Leufkens H
    South Med Rev; 2012 Dec; 5(2):34-41. PubMed ID: 23532710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Canadian Patented Medicine Prices Review Board. New rules and new status.
    Shulman SR
    Pharmacoeconomics; 1994; 6 Suppl 1():71-9. PubMed ID: 10155589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generic competition in Canada.
    Steele JW
    Pharmacoeconomics; 1994 Nov; 6(5):480-2. PubMed ID: 10155276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Price comparison of high-cost originator medicines in European countries.
    Vogler S; Zimmermann N; Babar ZU
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.
    Nunn AS; Fonseca EM; Bastos FI; Gruskin S; Salomon JA
    PLoS Med; 2007 Nov; 4(11):e305. PubMed ID: 18001145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of patented drug price on the share of new medicines across OECD countries.
    Spicer O; Grootendorst P
    Health Policy; 2022 Aug; 126(8):795-801. PubMed ID: 35654617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of external price referencing of pharmaceuticals in Middle East countries.
    Kaló Z; Alabbadi I; Al Ahdab OG; Alowayesh M; Elmahdawy M; Al-Saggabi AH; Tanzi VL; Al-Badriyeh D; Alsultan HS; Ali FM; Elsisi GH; Akhras KS; Vokó Z; Kanavos P
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):993-8. PubMed ID: 26088919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stakeholders' feedback on the proposed recommendations for updating the patented medicine prices review board (pmprb) budget impact analysis guidelines.
    Foroutan N; Tarride JE; Xie F; Jameel B; Mills F; Levine M
    J Popul Ther Clin Pharmacol; 2020 Jan; 27(1):e1-e24. PubMed ID: 31922700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the impact of the single exit price policy on a basket of originator medicines in South Africa from 1999 to 2014 using a time series analysis.
    Moodley R; Suleman F
    BMC Health Serv Res; 2019 Aug; 19(1):576. PubMed ID: 31419977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Product patents and access to innovative medicines.
    Dai R; Watal J
    Soc Sci Med; 2021 Dec; 291():114479. PubMed ID: 34700119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
    Stargardt T; Schreyögg J
    Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marketing before patenting: implications for price controls in Canada.
    Lexchin J
    Open Med; 2010; 4(3):e139-42. PubMed ID: 21687333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
    Roughead EE; Kim DS; Ong B; Kemp-Casey A
    WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of changes in the methodology of external price referencing on medicine prices: discrete-event simulation.
    Vogler S; Schneider P; Lepuschütz L
    Cost Eff Resour Alloc; 2020 Nov; 18(1):51. PubMed ID: 33292293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Contribution of Price Growth to Pharmaceutical Revenue Growth in the United States: Evidence from Medicines Sold in Retail Pharmacies.
    Kakani P; Chernew M; Chandra A
    J Health Polit Policy Law; 2022 Dec; 47(6):629-648. PubMed ID: 35867538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of branded prescription medicine prices in OECD countries.
    Kanavos PG; Vandoros S
    Health Econ Policy Law; 2011 Jul; 6(3):337-67. PubMed ID: 21676345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.